^
Association details:
| Biomarker: | EGFR L747P + PD-L1 overexpression |
|---|---|
| Cancer: | Non Small Cell Lung Cancer |
| Drug: | Keytruda (pembrolizumab) (PD1 inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
Immunotherapy in patients with lung cancer with driver mutations: A single center experience.
Published date:
05/19/2021
Excerpt:
EGFR was detected in 6 patients (3 on tumor and 3 in blood NGS)....Single agent checkpoint inhibitors seem to have a limited impact in treatment in patients with driver mutations....We do see benefit in patients who received PD1/PDL1 inhibitors in combination with chemotherapy with/ without Bevacizumab. In conclusion, patients progressing on EGFR TKIs who are planned for immunotherapy should always be given in combination with chemotherapy+/- Bevacizumab.
Secondary therapy:
carboplatin + pemetrexed
DOI:
10.1200/JCO.2021.39.15_suppl.e21170
